Interactions between the host immune response and the invading pathogen at the site of disease are crucial to the outcome of the infection. Leprosy, caused by the intracellular bacterium M. leprae, provides an extraordinary model for studying host-pathogen interactions in humans because the disease presents as a spectrum in which the clinical manifestations correlate with the level of immune response to the pathogen 1 . This allows for the investigation of the factors that contribute to the balance between host defense, persistence and pathogenesis at the site of disease in humans. At one end of the spectrum, in T-lep, the infection is self-limited, and skin lesions are typified by an adaptive immune response characterized by T helper type 1 (T H 1) cytokines 2,3 and an innate immune response characterized by macrophages programmed to express the vitamin D-mediated antimicrobial pathway 4 . At the other end of the spectrum, in L-lep, the infection is disseminated with lesions typified by an adaptive immune response characterized by T H 2 cytokines 2,3 and an innate immune response characterized by macrophages programmed to express a phagocytic activity 4 . To gain insight into the mechanisms that regulate host defense versus persistence in human infectious disease, we investigated miRNA expression in leprosy skin lesions.
Interactions between the host immune response and the invading pathogen at the site of disease are crucial to the outcome of the infection. Leprosy, caused by the intracellular bacterium M. leprae, provides an extraordinary model for studying host-pathogen interactions in humans because the disease presents as a spectrum in which the clinical manifestations correlate with the level of immune response to the pathogen 1 . This allows for the investigation of the factors that contribute to the balance between host defense, persistence and pathogenesis at the site of disease in humans. At one end of the spectrum, in T-lep, the infection is self-limited, and skin lesions are typified by an adaptive immune response characterized by T helper type 1 (T H 1) cytokines 2, 3 and an innate immune response characterized by macrophages programmed to express the vitamin D-mediated antimicrobial pathway 4 . At the other end of the spectrum, in L-lep, the infection is disseminated with lesions typified by an adaptive immune response characterized by T H 2 cytokines 2,3 and an innate immune response characterized by macrophages programmed to express a phagocytic activity 4 . To gain insight into the mechanisms that regulate host defense versus persistence in human infectious disease, we investigated miRNA expression in leprosy skin lesions.
RESULTS

Gene and miRNA profile in leprosy
The mRNA and miRNA expression profiles in skin lesions were determined in biopsy specimens from six individuals with T-lep and five individuals with L-lep collected at the time of diagnosis and classified according to the clinical and histopathological criteria of Ridley 1 (Supplementary Fig. 1 ). Unsupervised hierarchal clustering analysis of the mRNA profiles revealed two major groups in which the L-lep and T-lep samples were segregated (Supplementary Fig. 2 ). In contrast, hierarchal clustering analysis of the miRNA profiles performed on the same samples indicated two major miRNA patterns, with each group containing a mixture of both L-lep and T-lep samples (Supplementary Fig. 2 ). These results indicate that the principal component of the measured miRNA expression patterns in leprosy did not differentiate the lesion types.
To identify lesion-specific differences, we used a supervised approach. Differentially expressed miRNAs between the two clinical groups were identified by ranking miRNAs probes according to statistical significance (t test) and limited to sequences present in the miRBase database (version 14) . There was a fivefold higher number Leprosy provides a model to investigate mechanisms of immune regulation in humans, given that the disease forms a spectrum of clinical presentations that correlate with host immune responses. Here we identified 13 miRNAs that were differentially expressed in the lesions of subjects with progressive lepromatous (L-lep) versus the self-limited tuberculoid (T-lep) disease. Bioinformatic analysis revealed a significant enrichment of L-lep-specific miRNAs that preferentially target key immune genes downregulated in L-lep versus T-lep lesions. The most differentially expressed miRNA in L-lep lesions, hsa-mir-21, was upregulated in Mycobacterium leprae-infected monocytes. By directly downregulating Toll-like receptor 2/1 heterodimer (TLR2/1)-induced CYP27B1 and IL1B expression as well as indirectly upregulating interleukin-10 (IL-10), hsa-mir-21 inhibited expression of the genes encoding two vitamin D-dependent antimicrobial peptides, CAMP and DEFB4A. Conversely, knockdown of hsa-mir-21 in M. leprae-infected monocytes enhanced expression of CAMP and DEFB4A and restored TLR2/1-mediated antimicrobial activity against M. leprae. Therefore, the ability of M. leprae to upregulate hsa-mir-21 targets multiple genes associated with the immunologically localized disease form, providing an effective mechanism to escape from the vitamin D-dependent antimicrobial pathway.
of differentially expressed miRNAs in the L-lep samples (16 probes representing 13 annotated miRNA species) versus the T-lep samples (three probes representing two unique miRNA species) (Fig. 1a) . To compare the magnitude of differential expression between these miRNA species, we compared the un-normalized intensity values of the probes. The difference in intensity of the hsa-mir-21 probe was the greatest among the miRNA species differentially upregulated in L-lep versus T-lep lesions (Fig. 1b) .
Targeting of immune genes by leprosy-specific miRNAs
Because the differentially expressed miRNA species were predominantly enriched in L-lep lesions, we hypothesized that regulation of miRNA expression at the site of the progressive disease inhibits expression of genes involved in host defense against the pathogen. We tested this hypothesis by integrating a prediction algorithm for miRNA binding sites in the 3′ untranslated regions (3′ UTRs) of mRNA species within curated sets of host immune response signature genes known to be differentially expressed in leprosy lesions, including T H 1-versus T H 2-related genes as well as the genes of the vitamin D pathway (Supplementary Note). All miRNA species represented on the microarray platform were ranked by their 'targeting preference score' , calculated as the difference in frequency for targeting of the T-lep compared to L-lep signature genes ( Supplementary Fig. 3 and Supplementary Note). We next evaluated the enrichment of leprosy-disease-type-specific miRNA species by the KolmogorovSmirnov-based permutation test. On the basis of this analysis, we found the L-lep-specific miRNA species to be significantly associated with the miRNAs most strongly predicted to preferentially target Tlep signature genes (P = 0.049; Fig. 1c) . Thus, L-lep-specific miRNAs may be a mechanism for the M. leprae-induced downregulation of T-lep host immune response signature genes in L-lep lesions.
In relation to the local immune response, the L-lep-specific set of miRNA species were predicted to have binding sites in the 3′ UTRs of T H 1-related signature genes, known to be differentially expressed in T-lep versus L-lep lesions, with an average targeting frequency of 11.5%. In contrast, the L-lep-specific set of miRNAs species showed a significantly (P = 0.0003) lower targeting frequency for T H 2-related genes, known to be differentially expressed in L-lep versus T-lep lesions, with an average targeting frequency of 1.3% (Fig. 1d) . Notably, multiple L-lep-specific miRNA species targeted two key genes in the vitamin D-dependent antimicrobial pathway, encoding cytochrome P450, family 27, subfamily B, polypeptide 1 (CYP27B1) and IL-1β (IL1B), but not the genes encoding the antimicrobial peptides induced by this pathway, cathelicidin (LL-37, encoded by CAMP) and defensin β4A (DEFB4A) 5, 6 ( Fig. 1e) . Taken together, these results indicate that the L-lep-specific miRNAs target and potentially downregulate host defense genes in leprosy.
Regulation of hsa-mir-21 in leprosy
We verified the tissue expression of the most differentially expressed miRNA, hsa-mir-21, in L-lep lesions by real-time PCR (qPCR) and fluorescent in situ hybridization (FISH) in additional leprosy tissue sections. By qPCR, hsa-mir-21 levels were significantly higher (3.5-fold, P = 0.01) in 10 L-lep versus 11 T-lep lesions (Fig. 2a ). An unrelated miRNA, hsa-let-7c, that was not differentially expressed in disease lesions by microarray analysis, was expressed at similar levels between the L-lep and T-lep lesions (Fig. 2b) . Although the skin biopsies are composed predominately of granulomas in the dermis, we could not rule out that the differential expression of hsa-mir-21 came from nonimmune cells. Therefore, using FISH we determined that the frequency of hsa-mir-21-positive cells in the granulomatous regions was 25-fold higher in the L-lep lesions versus the T-lep lesions (98% versus 4% of nucleated cells, P = 0.001) (Fig. 2c) . In the L-lep lesions, the hsa-mir-21-positive cells were located within the granulomas, in the same microanatomic locations as M. leprae (Fig. 2d) . It was not possible to determine the frequency of cells expressing hsa-mir-21 and containing M. leprae, as these are found in distinct subcellular compartments: microRNAs are located in the cytoplasm and the pathogen resides within phagosomes. We used a scrambled probe as a negative control to demonstrate the absence of nonspecific binding in either lesion type ( Supplementary Fig. 4a ), and a positive control probe for the U6 noncoding small nuclear RNA showed equivalent RNA integrity (Supplementary Fig. 4b ). Taken together, these three approaches, microarray, qPCR and FISH, provide evidence for the differential expression of hsa-mir-21 in L-lep versus T-lep lesions. Given that we identified both M. leprae and hsa-mir-21 in the granulomas, we hypothesized that M. leprae induced hsa-mir-21 expression in monocytes and macrophages, the predominant cell type in a granuloma and the primary cell type infected by M. leprae. We infected human peripheral blood monocytes with live M. leprae at different multiplicities of infection (MOIs) for 18 and 40 h and measured hsa-mir-21 levels by qPCR. We efficiently infected monocytes with M. leprae ( Supplementary Fig. 5 ), which triggered an upregulation of hsa-mir-21 in a dose-dependent and time-responsive manner, with a 4.1-fold change (P = 0.005) at 18 h and 7.6-fold change (P = 0.00003) at 40 h, both at an MOI of 10 ( Fig. 3a) . In contrast, M. leprae infection of monocytes did not result in detectable upregulation of hsa-let-7c (Fig. 3b) .
To explore the mechanism by which M. leprae infection induces hsa-mir-21, we compared the ability of several key cell wall biomolecules to trigger hsa-mir-21 expression. Treatment of monocytes with phenolic glycolipid-I (PGL-I) induced a 2.9-fold increase in hsamir-21 expression, whereas the M. leprae lipoarabinomman (LAM) and lipomannan (LM), as well as a synthetic triacylated lipopeptide (a TLR2/1 ligand, TLR2/1L), did not significantly induce hsamir-21 (Fig. 3c) . Together, these data indicate that hsa-mir-21 is present at the site of disease in leprosy, is associated with the progressive and disseminated form (L-lep) of the disease, is specifically induced in monocytes by M. leprae infection and is triggered by an M. leprae-specific glycolipid, PGL-I. It is therefore likely that M. leprae infection of macrophages induces the upregulation of hsa-mir-21 at the site of infection. 
Regulation of the vitamin D pathway by hsa-mir-21
It was noteworthy that of all the L-lep-specific miRNAs, only hsa-mir-21 had the potential to target both IL1B and CYP27B1 (Fig. 1e) , which are both required for TLR-induced, vitamin D-dependent expression of CAMP and DEFB4A 5, 6 . We investigated the ability of hsa-mir-21 to regulate the expression of these antimicrobial genes by transfecting primary human monocytes with either the mature hsa-mir-21 oligomer or a nontargeting control oligomer, followed by activation with TLR2/1L. To determine the transfection efficiency of the miRNA oligomers into primary monocytes, we used a fluorescently tagged nontargeting control oligomer, which showed that 71% (P = 0.002) of the monocytes were miRNA positive (Supplementary Fig. 6 ). As a control for targeting specificity, we determined that overexpression of hsa-mir-21 downregulated interferon-γ-induced IL12A mRNA, a previously described direct target 7 (Supplementary Fig. 7) . The presence of hsa-mir-21 during TLR2/1L activation of monocytes resulted in the downregulation of IL1B mRNA by 24% (P = 0.006, representative experiment in Fig. 4a and averaged in Fig. 4b) . Despite the absence of predicted hsa-mir-21 target sites in the 3′ UTR of IL10, transfection of hsa-mir-21 enhanced TLR2/1-induced IL10 mRNA levels by 110% (P = 0.035, Fig. 4a,c) , consistent with studies in mouse cells 8 . In contrast, IL6 mRNA, another cytokine without hsa-mir-21 target sequences, was not affected (Fig. 4a,c) . TLR2/1-induced IL-1β secretion was reduced by 45% (P = 0.003), IL-10 release was enhanced by 85% (P = 0.001) and IL-6 levels did not change (representative experiment in Supplementary Fig. 8 and averaged in Fig. 4c) . Therefore, the effects of hsa-mir-21 on TLR2/1-induced cytokine mRNAs and secreted proteins were consistent. Transfection of hsa-mir-21 also resulted in a 34% decrease in TLR-induced expression of CYP27B1 mRNA (P = 0.008, Fig. 4a,b) .
Given that hsa-mir-21 downregulated TLR2/1-induced IL-1β and CYP27B1 mRNA expression, we examined the effect of hsa-mir-21 on TLR2/1-induced antimicrobial peptide gene expression. Notably, TLR2/1 induction of CAMP and DEFB4A mRNAs was significantly inhibited by transfection of hsa-mir-21, by 73% (P = 0.005) and 60% (P = 0.006), respectively (Fig. 4a,b) . Given that hsa-mir-21 upregulated IL-10, we investigated the effect of recombinant IL-10 on TLR2/1-induced gene expression. The addition of rIL-10 inhibited TLR2/1-induced mRNA expression of CAMP by 26% and DEFB4A by 35%, whereas the inhibition of IL12B was 76% (Supplementary Fig. 9a,b) . Therefore, hsa-mir-21-mediated enhancement of IL-10 induction may partially contribute to the inhibition of antimicrobial gene expression.
We assessed whether hsa-mir-21 directly binds the TLR2/1-induced, vitamin D-dependent antimicrobial pathway genes with a 3′ UTR reporter assay. hsa-mir-21 directly bound the 3′ UTRs of both CYP27B1 and IL1B but did not bind the 3′ UTRs of either CAMP or DEFB4A (Fig. 4d, Supplementary Fig. 10 and Supplementary Note). These data indicate that hsa-mir-21 inhibits TLR2/1-mediated CAMP and DEFB4A expression directly by regulating key epigenetic targets including CYP27B1 and IL1B and indirectly through induction of the immunomodulatory cytokine IL-10.
Role of hsa-mir-21 in the response to infection
Given the ability of hsa-mir-21 to downregulate key genes in the TLR2/1-induced antimicrobial pathway, and the observation that M. leprae induces hsa-mir-21 in monocytes, we investigated whether hsamir-21 contributes to inhibition of the innate immune response during M. leprae infection. We transfected monocytes with an hsa-mir-21-specific antisense oligomer (anti-mir-21), infected the transfected Figure 4 The ability of hsa-mir-21 to regulate the innate immune response in human monocytes. Primary human monocytes were transfected with the mature hsa-mir-21 (mir-21) oligomer or a nontargeting control (mir-neg) then treated with TLR2/1L for 18 h and 24 h. npg monocytes with live M. leprae 9 for 18 h and then measured mRNA expression. The presence of anti-mir-21 (versus a control oligomer (anti-mir-neg), followed by M. leprae infection, resulted in a significant reduction of hsa-mir-21 levels by 70% (P = 0.00002, Supplementary  Fig. 11a,c) . Consistent with the hsa-mir-21 overexpression experiment, anti-mir-21 enhanced IL12A mRNA expression in the M. lepraeinfected monocytes (P = 0.006, Supplementary Fig. 11b,c) .
Relevant to the vitamin D-dependent innate immune pathway, anti-mir-21 increased IL1B mRNA expression in the M. lepraeinfected monocytes by 118% (P = 0.047, Fig. 5a,b) . In contrast, IL10 mRNA was downregulated by 34% (P = 0.045), and there was no significant change in IL6 mRNA levels (Fig. 5a,b) . Notably, knockdown of hsa-mir-21 resulted in a significant increase in mRNA levels of CYP27B1 (59%, P = 0.014), CAMP (100%, P = 0.0006) and DEFB4A (227%, P = 0.014) (Fig. 5a,b) . These results provide evidence that monocytes and macrophages can detect M. leprae infection and trigger the vitamin D-dependent antimicrobial pathway; however, this response is inhibited by the pathogen's upregulation of hsa-mir-21.
Effects of hsa-mir-21 on innate antimicrobial activity
We investigated the role of hsa-mir-21 in regulating the TLR2/1-induced macrophage antimicrobial activity by overexpressing hsa-mir-21 during Mycobacterium tuberculosis infection. For these experiments, we used the avirulent M. tuberculosis H37Ra strain, as it does not contain a PGL-I homolog and failed to induce expression of hsa-mir-21 in monocytes upon infection (Supplementary Fig. 12a ), despite induction of IL6 mRNA in the same cells ( Supplementary  Fig. 12b) . We transfected monocytes with hsa-mir-21 or a control oligomer, infected them with M. tuberculosis H37Ra overnight, subsequently treated them with TLR2/1L for 3 d and assessed bacterial viability by qPCR according to the ratio of 16S RNA to the IS6110 genomic repeat element DNA 10 . TLR2/1L induced an antimicrobial activity against M. tuberculosis in monocytes transfected with a control oligomer (Fig. 6a) , at a level consistent with previous studies using the standard colony-forming unit assay (Supplementary Note) 6 . However, overexpression of hsa-mir-21 blocked the antimicrobial response and resulted in an increase in M. tuberculosis viability in TLR2/1L-activated cells (Fig. 6a) . Also, in unstimulated cells, hsamir-21 increased bacterial viability. Overall, M. tuberculosis viability in TLR2/1L-treated as compared to control monocytes was significantly higher in the presence of hsa-mir-21 (P = 0.01, Fig. 6b) .
To address the role of M. leprae-induced hsa-mir-21 in regulation of TLR2/1-induced antimicrobial activity, monocytes were transfected with anti-mir-21 or anti-mir-neg, then infected with live M. leprae. The transfected and infected cells were treated with the TLR2/1L for 3 d and antimicrobial activity assessed by qPCR by measuring the ratio of 16S RNA to RLEP DNA 10 . In anti-mir-neg transfected cells, TLR2/1-activation increased bacterial viability, consistent with previous findings indicating enhanced M. tuberculosis growth in TLR2/1-stimulated cells in the absence of CAMP and DEFB4A 6 . Strikingly, in anti-mir-21 transfected monocytes, TLR2/1-activation resulted in decreased bacterial viability (Fig. 6c) . The anti-mir-21 oligomer had no effect on M. leprae viability in unstimulated monocytes (Fig. 6c). a b In five donors tested, M. leprae viability in TLR2/1-stimulated cells was significantly lower in the presence of anti-mir-21 (P = 0.02, Fig. 6d) . Together, the data from these infection experiments demonstrate the biologic relevance of hsa-mir-21 in innate host defense: the expression of hsa-mir-21 is sufficient to block TLR2/1-induced antimicrobial responses and the silencing of hsa-mir-21 induction restores TLR2/1-mediated antimicrobial activity.
DISCUSSION
Host-pathogen interactions determine the outcome of the immune response to microbial infection. Our data provide evidence that the human pathogen M. leprae regulates the miRNA profile at the site of infection in humans with leprosy and interferes with the host antimicrobial response. We used a unique bioinformatic strategy, combining an enrichment analysis of leprosy-disease-type-specific miRNA species ranked by 3′ UTR mRNA targeting preference and evaluated by the Kolmogorov-Smirnov-based permutation test. leprae. Therefore, these data identify an evasion strategy in which a microbial pathogen regulates the host miRNA profile at the site of infection to inhibit the antimicrobial response. Although M. leprae was the first human pathogen discovered 11 , it still cannot be grown in the laboratory, providing a major obstacle to investigation of the immunology of leprosy. To our knowledge, it has not been possible to demonstrate immune-mediated antimicrobial activity against M. leprae in primary human cells 12 . A previous comparison of antimicrobial responses in mouse and human macrophages demonstrated that the combination of lipopolysaccharide and interferon-γ reduced the viability of intracellular M. leprae in mouse but not human macrophages 12 . Here we successfully demonstrate that immune activation of M. leprae-infected human monocytes decreases bacterial viability, finding that TLR2/1 activation induced a fourfold reduction in M. leprae viability only when hsa-mir-21 was silenced. In addition, overexpression of hsa-mir-21 blocked the TLR2/1-induced antimicrobial activity against M. tuberculosis, resulting in a fivefold increase in bacterial viability. Taken together, these data indicate the biological relevance of hsa-mir-21 in the host antimicrobial response.
We gained insight into the mechanism by which M. leprae induces a specific miRNA immune regulatory profile at the site of infection by finding that hsa-mir-21 was induced in monocytes after M. leprae infection or by treatment with M. leprae-derived PGL-I. Previously, PGL-I has been shown to inhibit monocyte responses 13, 14 , as well as associate with mycobacterial virulence 15 . Further studies are needed to elucidate the mechanism of induction and functional role of those miRNAs differentially expressed in L-lep lesions. Given that the degree of genetic diversity in M. leprae clinical isolates is not as broad as compared with other human pathogens 16 , it is not likely that species subtypes differentially induce single miRNAs, as has been shown for Francisella tularensis 17 . To complement the study of miRNA profiles in disease lesions as shown here, additional insight can be obtained by profiling the miRNAs induced by a pathogen in an isolated cell type 18 . It should be possible to learn whether the ability of a pathogen to induce a single miRNA or set of miRNA species that targets and inhibits host immune responses provides a potential virulence mechanism that contributes to the pathogenesis of infectious disease 19 .
Our data demonstrate that a single miRNA species, by both directly and indirectly regulating immune modulatory genes, can affect the downstream effectors of an innate immune-triggered antimicrobial pathway. Specifically, hsa-mir-21 inhibited TLR2/1-induced CYP27B1 and IL1B gene expression and enhanced IL-10 expression, thereby preventing upregulation of the CAMP and DEFB4 mRNAs, which encode antimicrobial peptides. These factors are all key to the outcome of the vitamin D antimicrobial pathway: (i) CYP27b1 converts vitamin D from an inactive to active state, leading to antimicrobial activity, (ii) IL-1β is required for DEFB4 induction and (iii) IL-10 is known to inhibit TLR-induced responses 20 . Consequently, hsa-mir-21 inhibits the innate immune response by its distinct gene regulatory activities: the indirect upregulation of an immunosuppressive cytokine and direct targeting of epigenetic components required for the TLR-induced, vitamin D-dependent antimicrobial pathway 5, 6 . Consistent with this model, the genes directly targeted by hsa-mir-21, CYP27B1 and IL1B, are downregulated in L-lep versus T-lep lesions 2, 4 . Although the relationship between expression of miRNAs and gene targets in disease lesions is correlative, the demonstration that hsa-mir-21 is induced in human primary monocytes 18 h after M. leprae infection and its effect on the TLR-induced antimicrobial response suggest a role in disease pathogenesis. Our investigation of the effect of a single miRNA in leprosy provides a framework for analyzing the set of miRNAs that are differentially expressed at the site of disease to determine their cumulative role in regulating the host immune response, including autophagy and antimicrobial pathways.
The ability of anti-mir-21 to enhance the vitamin D-dependent antimicrobial pathway provides a potential therapeutic strategy to intervene in human infectious disease. In leprosy, the vitamin D antimicrobial pathway may contribute to disease outcome, on the basis of the preferential expression of antimicrobial pathway genes in the T-lep versus L-lep form 4 , the correlation of the vitamin D receptor single-nucleotide polymorphism in humans with L-lep 21 and the reported successful use of vitamin D as a therapeutic adjuvant in the treatment of leprosy 22 . Potentially, the combination of vitamin D supplementation with targeted miRNA therapy could provide an optimal treatment approach to leprosy and other chronic infectious diseases in which the cellular immune response is dysregulated. This type of approach may be particularly worth exploring in the clinical setting of drug-resistant pathogens, including multi-drug-resistant, extremely drug-resistant and totally drug-resistant tuberculosis, in which antimicrobial therapy is losing its effectiveness. Finally, our findings may be relevant to other diseases, including infectious 23, 24 , autoimmune 25 and neoplastic 26, 27 diseases in which vitamin D sufficiency has been shown to be required for optimal host immunity.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
